Market revenue in 2023 | USD 190.3 million |
Market revenue in 2030 | USD 280.1 million |
Growth rate | 5.7% (CAGR from 2023 to 2030) |
Largest segment | Large molecules |
Fastest growing segment | Small molecules |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Large Molecules, Small molecules |
Key market players worldwide | Boehringer Ingelheim, Catalent Inc, Baxter International Inc, Eurofins Scientific SE, Recipharm, Fresenius SE & Co KGaA, Novartis AG ADR, Recro Pharma, Symbiosis Pharmaceutical Services, MabPlex International |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fill-finish pharmaceutical contract manufacturing market will help companies and investors design strategic landscapes.
Large molecules was the largest segment with a revenue share of 67.1% in 2023. Horizon Databook has segmented the Italy fill-finish pharmaceutical contract manufacturing market based on large molecules, small molecules covering the revenue growth of each sub-segment from 2018 to 2030.
The fill-finish pharmaceutical contract manufacturing industry in Italy is growing with several companies offering these services. Fill-finish manufacturing refers to the final stages of the drug manufacturing process, which involves filling the drug into containers, such as vials or syringes, and finishing it with labeling & packaging.
The COVID-19 pandemic has had an impact on the fillfinish pharmaceutical contract manufacturing scenario in Italy, as many companies have been increasing the production of vaccines and therapeutics. Some Italian CMOs have been involved in the production of COVID-19 vaccines, such as Stevanato Group, which has partnered with several vaccine developers to provide fill-finish services.
Moreover, the growing demand for the production of biologics and biosimilars in Italy is also one of the primary drivers of the market. The Italian government has implemented policies that support the growth of pharmaceutical companies that produce biologics and biosimilars. In 2018, the Italian Ministry of Health funded a 4-year project named Assessment of short- and long-term risk−benefit profiles of biologicals through a healthcare database network in Italy.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy fill-finish pharmaceutical contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Italy fill-finish pharmaceutical contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account